Bizengri (zenocutuzumab-zbco) won an FDA label expansion for adults with advanced, unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy, backed by a 36.8% confirmed overall response rate in 19 efficacy-evaluable patients from the Phase I/II eNRGy trial. The decision gives the HER2/HER3-directed bispecific antibody its third tumor indication and was completed more than five months ahead of the FDA goal date under the agency's national priority voucher pilot program.

Why It Matters To Oncology

• NRG1 fusions are rare but actionable drivers, and this approval adds a targeted option for a bile duct cancer population with limited post-progression treatments.

• The expansion reinforces basket-style development in genomically defined tumors, with cholangiocarcinoma joining prior accelerated approval settings in non-small cell lung cancer and pancreatic adenocarcinoma.

• For clinicians, the key efficacy signal came from a single-arm cohort: 7 responses among 19 evaluable patients, with duration of response ranging from 2.8 to 12.9 months by blinded independent central review.

The Financials

• Bizengri was originally developed by Merus and is now commercialized in the U.S. by Partner Therapeutics under a 2024 licensing deal.

• The approval is the seventh under the FDA's national priority voucher pilot, a program designed to compress review timelines for selected applications.

• Speed matters commercially: the agency finished this review more than five months early, potentially accelerating uptake in a niche biomarker-defined market.

What They're Saying

• The FDA's action signals continued regulatory willingness to support precision oncology drugs in rare fusion-driven cancers using strong response data from small, single-arm studies.

• The label expansion also underscores momentum behind pan-tumor biomarker strategies when the alteration is biologically compelling and testing can identify eligible patients.

• In practice, this puts added focus on comprehensive molecular profiling in cholangiocarcinoma to detect NRG1 fusions that might otherwise be missed.

What's Next

• Clinicians will watch how broadly NRG1 fusion testing is adopted in bile duct cancer and whether community settings can consistently identify eligible patients.

• Longer follow-up from eNRGy should help clarify durability, sequencing and real-world tolerability as use expands across tumor types.

• Bizengri is given by IV infusion every two weeks until disease progression or unacceptable toxicity, so operational fit and payer access will help determine near-term uptake.